| Sample type | Serum | Exosome-enriched serum | FFPE tissue |
DLBCL patients | ||||
| Number (Female; male) | 33 (13; 20) | 28 (12; 16) | 22 (9; 13) |
| Age, median (range) | 67 (36 - 84) | 68.5 (38 - 84) | 67.5 (46 - 83) |
Stage | I | 3 | 2 | 2 |
II | 7 | 7 | 3 | |
III | 6 | 4 | 5 | |
IV | 17 | 15 | 12 | |
B symptom | 10 | 9 | 9 | |
Performance status at diagnosis | 0, 1, 2 | 30 | 25 | 20 |
3, 4 | 3 | 3 | 2 | |
Serum lactate dehydrogenase (LDH) level, IU/L | Median (range) | 237 (138 - 8472) | 242 (138 - 8472) | 276.5 (161 - 8472) |
Elevated (>240) | 16 | 14 | 12 | |
Extra nodal disease, number | 0 | 12 | 10 | 8 |
1 | 12 | 11 | 10 | |
2 | 8 | 6 | 4 | |
3 | 1 | 1 | 0 | |
International Prognostic Index (IPI) | Low | 6 | 4 | 2 |
Low-intermediate | 15 | 12 | 12 | |
High-intermediate | 8 | 8 | 6 | |
High | 4 | 4 | 2 | |
Immunohistochemical grouping (Hans’ algorithm) | GCB | 14 | 13 | 8 |
Non-GCB | 16 | 13 | 12 | |
Not applicable | 3 | 2 | 2 | |
Healthy volunteers (control) | ||||
| Number (Female; male) | 22 (9; 13) | 19 (9; 10) | 6* (5; 1) |
| Age, median (range) | 62 (20 - 76) | 62 (39 - 76) | 51.5 (40 - 69) |